Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin.
Fietzek
Urban M
UM
Schroeteler
Frauke E
FE
Ceballos-Baumann
Andres O
AO
D000368:Aged; D001905:Botulinum Toxins / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D008297:Male; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D020734:Parkinsonian Disorders / Q000150:complications; D013121:Spinal Curvatures / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
D009465:Neuromuscular Agents; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A; C545476:incobotulinumtoxinA